Repligen Receives FDA Fast Track Designation For RG1068 For Pancreatic Imaging

Repligen Corporation (Nasdaq: RGEN) announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the development program for RG1068, synthetic human secretin, to improve the assessment of pancreatic duct structures by magnetic resonance imaging (MRI). Fast track is a process designed to facilitate the development and expedite the review of drugs that treat serious diseases and fill an unmet medical need.

More: continued here

Filed under: GastroIntestinal / Gastroentorology on April 17th, 2008